Research Explorer

Project

The study of the therapeutic potential of PPARα-ERRα ligand combinations in metabolic dysfunction-associated steatotic liver disease
Code
01CD10024
Duration
01 November 2024 → 30 June 2025
Funding
Regional and community funding: Special Research Fund
Research disciplines
  • Medical and health sciences
    • Hepatology
Keywords
ligand combination murine MASLD,MASH, and HCC models Hepatology medical transcriptomics transcription and translation regulation of metabolism
 
Project description
 Metabolic dysfunction-associated steatotic liver disease (MASLD) has become the most common liver disease worldwide. Two nuclear receptors (NR), peroxisome proliferator-activated receptor alpha (PPARα) and estrogen-related receptor alpha (ERRα), involved in hepatic energy metabolism are druggable targets against MASLD. Recently, a close functional interconnection was described. Therefore, we studied whether simultaneous pharmacological modulation of PPARα and ERRα can ameliorate MASLD.